Canadian Supreme Court decision on GlaxoSmithKline’s transfer pricing

International Tax Review is part of Legal Benchmarking Limited, 1-2 Paris Garden, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Canadian Supreme Court decision on GlaxoSmithKline’s transfer pricing

The Canadian Supreme Court (SC) has today delivered its first transfer pricing decision, in a case involving GlaxoSmithKline (GSK).

gsk150.jpg

The SC dismissed the appeal by the Canada Revenue Agency (CRA) of a ruling by the Federal Court concerning the deductibility of the price paid by GSK Canada to a Swiss related-entity. The CRA said the payment was not reasonable in the circumstances and a reasonable payment would have been that paid by generic companies.

GSK Canada said the consideration of reasonableness should take into account the licence agreement between the GSK group of companies and GSK Canada, which agreed a 6% royalty should be paid to the GSK group on sales of drugs covered by the agreement.

The trial judge ignored this and ruled the price GSK Canada should have paid was the highest of that paid by generic companies. This was overruled by the Federal Court in July 2010.

It has taken the SC judges 10 months to come to a decision after the hearing on January 13.

The SC held that the determination of an arm’s-length price must be informed by relevant surrounding economic circumstances, including other transactions that may be related to the purchasing transaction.

The case will now return to the Tax Court of Canada for redetermination because the SC also dismissed GSK’s cross-appeal, which asked it to overturn the decision of the Federal Court of Appeal to remit the matter to the Tax Court.

How GSK’s Canada SC hearing unfolded

Canadian Supreme Court confirms GSK date

GlaxoSmithKline files its arguments to Supreme Court of Canada

Supreme Court of Canada accepts Glaxo case

Glaxo prevails in the Canadian Federal Court of Appeal

Glaxo Canada: the key issues

Glaxo Canada loses transfer pricing case

more across site & shared bottom lb ros

More from across our site

Tax expert Craig Hillier agrees with the comparison of pillar two to using a sledgehammer to crack a nut
The amount is reported to be up 57% from the £5.6bn that the UK tax agency believes was underpaid in the previous year
The US president also unveiled a new 50% levy on copper imports; in other news, a UK wealth tax proposal has been criticised by the Institute for Fiscal Studies
Wim Wuyts, who had been head of the specialist tax network since 2017, is moving on to a new role with WTS’s Belgian member firm
MNEs are increasingly using algorithmic tools in TP. Sahasranshu Dash argues that data ethics should therefore plug directly into the TP design process
The Institute of Chartered Accountants in England and Wales also queried whether HMRC resources could be better spent scrutinising larger entities
Grant Thornton’s Austria tax head likens his practice to an escape room, shares his football coaching ambitions, and explains why tax is cool
Awards
ITR is delighted to reveal all the shortlisted nominees for the 2025 EMEA Tax Awards
Awards
ITR is delighted to reveal all the shortlisted nominees for the 2025 Asia-Pacific Tax Awards
The fates of pillars one and two hang in the balance after the US successfully threw its weight around in G7 and Canadian negotiations
Gift this article